John Tsai
Director/Board Member presso BLUEPRINT MEDICINES CORPORATION
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Attualmente, John Tsai è Chief Medical Officer presso Novartis AG. Nella sua carriera passata il Dr. Tsai è stato Chief Medical Officer & SVP-Global Medical presso Amgen, Inc. e Head-Clinical Development presso Bristol Myers Squibb Co. Ha ricevuto un dottorato dalla University of Louisville School of Medicine e una laurea presso la Washington University di St.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NOVARTIS AG
0.00% | 31/12/2022 | 13 550 ( 0.00% ) | 1 M $ | 31/03/2024 |
| 21/06/2023 | 6 500 ( 0.01% ) | 616 590 $ | 31/03/2024 |
Posizioni attive di John Tsai
| Società | Posizione | Inizio |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 06/01/2023 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
| Forcefield Therapeutics Ltd. | Chief Executive Officer | 27/09/2023 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 16/10/2023 |
Precedenti posizioni note di John Tsai
| Società | Posizione | Fine |
|---|---|---|
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | 15/05/2022 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/01/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 01/01/2012 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
Formazione di John Tsai
| Washington University in St. Louis | Undergraduate Degree |
| University of Louisville School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NOVARTIS AG | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Aziende private | 4 |
|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Forcefield Therapeutics Ltd. |
- Borsa valori
- Insiders
- John Tsai
